 phase II trial high-dose cisplatin dacarbazine Lack efficacy high-dose cisplatin-based therapy metastatic melanoma Cisplatin dacarbazine treatment metastatic melanoma high-dose cisplatin dacarbazine patients metastatic melanoma cisplatin days intervals median age years range years median Karnofsky performance status range Measurable evaluable disease sites number patients lymph nodes lung soft tissue bone spleen adrenal gland sites median cycles therapy range cycles Thirty patients evaluable response complete responses patients partial response confidence interval months sites disease lymph nodes lung soft tissue Hematologic toxicity Grade equal neutropenia patients cycles thrombocytopenia patients cycles anemia patients Nine neutropenia fever patients bacteremia Nonhematologic toxicity Grade equal hypotension patients nausea vomiting neuropathy ototoxicity hypomagnesemia low objective response rate severe toxicity regimen standard use patients metastatic melanoma review cisplatin-based therapy metastatic melanoma dose-response relationship use high-dose cisplatin treatment metastatic melanoma